GlassScriptPhysician profile
Soma Jyothula
NPI 1770669624
$128,856.57
in general payments reported to CMS, 2019-2025
37 companies · $20K in 2025
The $20K reported for 2025 was more than what 95% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $13K · 2021: $16K · 2022: $9,150 · 2023: $23K · 2024: $11K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Consulting Fee: $5,760 · Food and Beverage: $3,657 · Travel and Lodging: $2,450 · Education: $83.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,550.00 |
| Consulting Fee | $5,760.00 |
| Food and Beverage | $3,657.10 |
| Travel and Lodging | $2,449.87 |
| Education | $83.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $92,686.98 | 2019-2025 | Ofev, Jascayd |
| Genentech USA, INC. | $30,950.26 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $1,319.13 | 2019-2025 | Uptravi, Opsumit |
| United Therapeutics Corporation | $715.52 | 2019-2025 | Tyvaso, Steen Solution, Tyvaso |
| Abbott Laboratories | $493.73 | 2023-2024 | Cardiomems |
| Astellas Pharma US INC | $410.91 | 2019-2025 | Cresemba |
| Bayer Healthcare Pharmaceuticals INC. | $369.32 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $216.68 | 2019-2025 | Farxiga, Lokelma |
| Xvivo Perfusion INC. | $181.99 | 2023 | |
| Pulmonx Corporation | $176.46 | 2019-2021 | |
| Intuitive Surgical, INC. | $153.84 | 2025 | |
| Glaxosmithkline, LLC. | $146.21 | 2023-2024 | Arexvy, Trelegy Ellipta |
| Livanova USA, INC. | $134.14 | 2020 | |
| Grifols USA, LLC | $112.19 | 2019-2025 | Prolastin-C Liquid |
| Olympus America INC. | $87.76 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $71.24 | 2019-2025 | Arikayce |
| Allergan, INC. | $71.17 | 2019 | |
| Cvrx, INC. | $62.28 | 2024-2025 | Barostim Neo System |
| Sandoz INC. | $56.27 | 2022-2024 | Treprostinil |
| Novo Nordisk INC | $51.85 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $50.35 | 2024-2025 | Winrevair |
| E.R. Squibb & Sons, L.L.C. | $40.44 | 2025 | Camzyos |
| Baxter Healthcare | $36.59 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.40 | 2025 | Glassia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.78 | 2020-2021 | |
| Inari Medical, INC. | $24.78 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Gilead Sciences, INC. | $22.93 | 2019 | |
| Advanced Respiratory, INC | $20.13 | 2020 | |
| Medtronic Vascular, INC. | $16.78 | 2019 | |
| Electromed, INC. | $16.70 | 2025 | Smartvest |
| Sensible Medical Innovations INC | $16.33 | 2025 | Reds System |
| Vifor Pharma, INC. | $16.12 | 2021 | |
| Pfizer INC. | $15.66 | 2020 | |
| Abiomed | $14.79 | 2023 | Impella |
| Xeris Pharmaceuticals, INC. | $14.04 | 2023 | Keveyis |
| Smith+Nephew, INC. | $12.82 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soma Jyothula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.